Vifor International Inc. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.
This is a non-interventional, cross-sectional, multicentre, and multinational (European) study. The non-interventional study (NIS) design allows the observation of patients in large haemodialysis (HD) centres reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by the sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour. The CENSUS-EU represents a cross-sectional study design of a representative selection of patients undergoing HD at 113 large dialysis centres across 7 countries in Europe. Prot. v.2.0, 9 May 2023
Study Type
OBSERVATIONAL
Enrollment
3,100
Prevalence of CKD-aP in HD patients
Percentage (%)
Time frame: A 7-month study timeline
The prevalence of CKD-aP by severity
none, mild, moderate, and severe
Time frame: A 7-month study timeline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1113
Aschaffenburg, Germany
1011
Balingen, Germany
1007
Braunschweig, Germany
1016
Einbeck, Germany
1012
Eisenach, Germany
1043
Flensburg, Germany
1048
Freiburg im Breisgau, Germany
1049
Freiburg im Breisgau, Germany
1046
Hanover, Germany
1001
Herne, Germany
...and 84 more locations